We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TOL.ST

Price
0.41
Stock movement up
+0.01 (1.74%)
Company name
Toleranzia AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
111.09M
Ent value
128.21M
Price/Sales
4.68
Price/Book
0.75
Div yield
195.12%
Div growth
-
Growth years
2
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-33.90%
1 year return
-15.81%
3 year return
-32.19%
5 year return
-
10 year return
-
Last updated: 2025-04-15

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share0.80
Dividend yield195.12%
Payout frequencyQuarterly
Maximum yield246.15%
Average yield141.39%
Minimum yield64.00%
Discount to avg yield27.54%
Upside potential38.01%
Yield as % of max yield79.27%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield195.12%
Current yield distribution7.35%
Yield at 100% (Min)64.00%
Yield at 90%87.09%
Yield at 80%105.32%
Yield at 50% (Median)144.93%
Yield at 20%169.49%
Yield at 10%188.37%
Yield at 0% (Max)246.15%

Dividend per share

Dividend per share data
Years of growth2 years
CCC status-
Dividend per share0.80
Payout frequencyQuarterly
Ex-div date5 Jan 2023
EPS (TTM)-0.04
EPS (1y forward)-
EPS growth (5y)-33.90%
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
TOL.STS&P500
DGR MR17.65%-13.74%
DGR TTM17.65%6.60%
DGR 3 years20.51%5.24%
DGR 5 years-5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced1134 days
EPS growth (5y)-33.90%
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward--

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales4.68
Price to Book0.75
EV to Sales5.40

FINANCIALS

Per share

Per share data
Current share count270.96M
EPS (TTM)-0.04
FCF per share (TTM)-0.20

Income statement

Income statement data
Revenue (TTM)23.75M
Gross profit (TTM)34.40M
Operating income (TTM)-8.62M
Net income (TTM)-7.12M
EPS (TTM)-0.04
EPS (1y forward)-

Margins

Margins data
Gross margin (TTM)144.84%
Operating margin (TTM)-36.28%
Profit margin (TTM)-29.98%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash1.04M
Net receivables1.69M
Total current assets2.73M
Goodwill0.00
Intangible assets163.50M
Property, plant and equipment0.00
Total assets166.46M
Accounts payable8.43M
Short/Current long term debt7.50M
Total current liabilities10.66M
Total liabilities18.16M
Shareholder's equity148.31M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-4.78M
Capital expenditures (TTM)35.40M
Free cash flow (TTM)-40.18M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-4.80%
Return on Assets-4.28%
Return on Invested Capital-4.80%
Cash Return on Invested Capital-27.09%

STOCK INFORMATION

Stock chart

Stock price data
Open0.39
Daily high0.41
Daily low0.39
Daily Volume20K
All-time high1.88
1y analyst estimate-
Beta1.33
EPS (TTM)-0.04
Dividend per share0.80
Ex-div date5 Jan 2023
Next earnings date-

Downside potential

Downside potential data
TOL.STS&P500
Current price drop from All-time high-78.13%-12.04%
Highest price drop-82.67%-56.47%
Date of highest drop17 Mar 20259 Mar 2009
Avg drop from high-48.97%-11.07%
Avg time to new high378 days12 days
Max time to new high929 days1805 days
COMPANY DETAILS
TOL.ST (Toleranzia AB) company logo
Marketcap
111.09M
Marketcap category
Small-cap
Description
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, it develops tolerogens proteins technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
Employees
11
Website
https://www.toleranzia.se
Investor relations
-
SEC filings
TOL.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved